[1] Dasari A, Shen C, Halperin D, et al.  Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states[J]. JAMA Oncol, 2017, 3(10): 1335-1342.   doi: 10.1001/jamaoncol.2017.0589
[2] Rindi G, Klimstra DS, Abedi-Ardekani B, et al.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal[J]. Mod Pathol, 2018, 31(12): 1770-1786.   doi: 10.1038/s41379-018-0110-y
[3] Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, et al.  Neuroendocrine tumor heterogeneity adds uncertainty to the World Health Organization 2010 Classification: real-world data from the Spanish Tumor Registry (R-GETNE)[J]. Oncologist, 2018, 23(4): 422-432.   doi: 10.1634/theoncologist.2017-0364
[4] Mukherjee A, Agarwal KK, Bal C, et al.  FDG DOTANOC mismatch in in vivo characterization and grading of neuroendocrine tumor[J]. Clin Nucl Med, 2016, 41(12): e511-e513.   doi: 10.1097/RLU.0000000000001399
[5] Rozenblum L, Mokrane FZ, Yeh R, et al.  The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI[J]. Abdom Radiol (NY), 2019, 44(7): 2474-2493.   doi: 10.1007/s00261-019-01994-5
[6] Waseem N, Aparici CM, Kunz PL.  Evaluating the role of theranostics in grade 3 neuroendocrine neoplasms[J]. J Nucl Med, 2019, 60(7): 882-891.   doi: 10.2967/jnumed.118.217851
[7]

Carideo L, Prosperi D, Panzuto F, et al. Role of combined [68Ga]Ga-DOTA-SST analogues and [18F]FDG PET/CT in the management of GEP-NENs: a systematic review[J/OL]. J Clin Med, 2019, 8(7): 1032[2020-08-24]. https://www.mdpi.com/2077-0383/8/7/1032. DOI: 10.3390/jcm8071032.
[8]

Mansi R, Abid K, Nicolas GP, et al. A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting[J/OL]. EJNMMI Res, 2020, 10(1): 90[2020-08-24]. https://ejnmmires.springeropen. com/articles/10.1186/s13550-020-00677-3. DOI: 10.1186/s1355 0-020-00677-3.
[9] Basu S, Parghane RV, Kamaldeep, et al.  Peptide receptor radionuclide therapy of neuroendocrine tumors[J]. Semin Nucl Med, 2020, 50(5): 447-464.   doi: 10.1053/j.semnuclmed.2020.05.004
[10] 刘炳楠, 王颖, 要少波.  神经内分泌肿瘤核医学显像剂的研究进展[J]. 国际放射医学核医学杂志, 2020, 44(9): 582-588.   doi: 10.3760/cma.j.cn121381-201906012-00062
Liu BN, Wang Y, Yao SB.  Research progress of nuclear medicine imaging tracers for neuroendocrine neoplasma[J]. Int J Radiat Med Nucl Med, 2020, 44(9): 582-588.   doi: 10.3760/cma.j.cn121381-201906012-00062
[11] Lee I, Paeng JC, Lee SJ, et al.  Comparison of diagnostic sensitivity and quantitative indices between 68Ga-DOTATOC PET/CT and 111In-pentetreotide SPECT/CT in neuroendocrine tumors: a preliminary report[J]. Nucl Med Mol Imaging, 2015, 49(4): 284-290.   doi: 10.1007/s13139-015-0356-y
[12] Van Binnebeek S, Vanbilloen B, Baete K, et al.  Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours[J]. Eur Radiol, 2016, 26(3): 900-909.   doi: 10.1007/s00330-015-3882-1
[13] Barrio M, Czernin J, Fanti S, et al.  The impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis[J]. J Nucl Med, 2017, 58(5): 756-761.   doi: 10.2967/jnumed.116.185587
[14] Treglia G, Castaldi P, Rindi G, et al.  Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis[J]. Endocrine, 2012, 42(1): 80-87.   doi: 10.1007/s12020-012-9631-1
[15] Frilling A, Sotiropoulos GC, Radtke A, et al.  The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors[J]. Ann Surg, 2010, 252(5): 850-856.   doi: 10.1097/SLA.0b013e3181fd37e8
[16] Niederle B, Pape UF, Costa F, et al.  ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum[J]. Neuroendocrinology, 2016, 103(2): 125-138.   doi: 10.1159/000443170
[17] Falconi M, Eriksson B, Kaltsas G, et al.  ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors[J]. Neuroendocrinology, 2016, 103(2): 153-171.   doi: 10.1159/000443171
[18] Kayani I, Bomanji JB, Groves A, et al.  Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG[J]. Cancer, 2008, 112(11): 2447-2455.   doi: 10.1002/cncr.23469
[19] Rinzivillo M, Partelli S, Prosperi D, et al.  Clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography in the diagnostic algorithm of advanced entero-pancreatic neuroendocrine neoplasms[J]. Oncologist, 2018, 23(2): 186-192.   doi: 10.1634/theoncologist.2017-0278
[20] 臧士明, 艾书跃, 姚晓晨, 等.  18F-FDG及68Ga-DOTA-NOC PET/CT对G3神经内分泌肿瘤的诊断比较[J]. 中华核医学与分子影像杂志, 2017, 37(4): 202-206.   doi: 10.3760/cma.j.issn.2095-2848.2017.04.003
Zang SM, Ai SY, Yao XC, et al.  Comparison of 18F-FDG and 68Ga-DOTA-NOC PET/CT on the diagnosis of G3 neuroendocrine neoplasm[J]. Chin J Nucl Med Mol Imaging, 2017, 37(4): 202-206.   doi: 10.3760/cma.j.issn.2095-2848.2017.04.003
[21] Naswa N, Sharma P, Gupta SK, et al.  Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?[J]. Clin Nucl Med, 2014, 39(1): e27-e34.   doi: 10.1097/RLU.0b013e31827a216b
[22] Ilhan H, Fendler WP, Cyran CC, et al.  Impact of 68Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum[J]. Ann Surg Oncol, 2015, 22(1): 164-171.   doi: 10.1245/s10434-014-3981-2
[23]

Chen SH, Chang YC, Hwang TL, et al. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: a prospective study in Taiwan[J/OL]. J Formos Med Assoc, 2018, 117(6): 480−487[2020-08-24]. https://www.sciencedirect.com/science/article/pii/S092966461730308X?via%3Dihub. DOI: 10.1016/j.jfma.2017.07.007.
[24] Cingarlini S, Ortolani S, Salgarello M, et al.  Role of combined 68Ga-DOTATOC and 18F-FDG positron emission tomography/computed tomography in the diagnostic workup of pancreas neuroendocrine tumors: implications for managing surgical decisions[J]. Pancreas, 2017, 46(1): 42-47.   doi: 10.1097/MPA.0000000000000745
[25] Pape UF, Böhmig M, Berndt U, et al.  Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center[J]. Ann N Y Acad Sci, 2004, 1014(1): 222-233.   doi: 10.1196/annals.1294.025
[26] Tomimaru Y, Eguchi H, Tatsumi M, et al.  Clinical utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors[J]. Surgery, 2015, 157(2): 269-276.   doi: 10.1016/j.surg.2014.09.011
[27]

Zhang PP, Yu JY, Li J, et al. Clinical and prognostic value of PET/CT imaging with combination of 68Ga-DOTATATE and 18F-FDG in gastroenteropancreatic neuroendocrine neoplasms[J/OL]. Contrast Media Mol Imaging, 2018, 2018: 2340389[2020-08-24]. https://www.hindawi.com/journals/cmmi/2018/2340389. DOI: 10.1155/2018/2340389.
[28] Abdulrezzak U, Kurt YK, Kula M, et al.  Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors[J]. Nucl Med Commun, 2016, 37(8): 874-881.   doi: 10.1097/MNM.0000000000000522
[29] Fisseler-Eckhoff A, Demes M.  Neuroendocrine tumors of the lung[J]. Cancers (Basel), 2012, 4(3): 777-798.   doi: 10.3390/cancers4030777
[30] Kayani I, Conry BG, Groves AM, et al.  A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors[J]. J Nucl Med, 2009, 50(12): 1927-1932.   doi: 10.2967/jnumed.109.066639
[31] Severi S, Nanni O, Bodei L, et al.  Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2013, 40(6): 881-888.   doi: 10.1007/s00259-013-2369-z
[32]

Oh S, Prasad V, Lee DS, et al. Effect of peptide receptor radionuclide therapy on somatostatin receptor status and glucose metabolism in neuroendocrine tumors: intraindividual comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT[J/OL]. Int J Mol Imaging, 2011, 2011: 524130[2020-08-24]. https://www.hindawi.com/journals/ijmi/2011/524130. DOI: 10.1155/2011/524130.
[33] Kaltsas GA, Besser GM, Grossman AB.  The diagnosis and medical management of advanced neuroendocrine tumors[J]. Endocr Rev, 2004, 25(3): 458-511.   doi: 10.1210/er.2003-0014
[34] Raymond E, Dahan L, Raoul JL, et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6): 501-513.   doi: 10.1056/NEJMoa1003825
[35] Yao JC, Shah MH, Ito T, et al.  Everolimus for advanced pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6): 514-523.   doi: 10.1056/NEJMoa1009290
[36] Thapa P, Ranade R, Ostwal V, et al.  Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics[J]. Nucl Med Commun, 2016, 37(10): 1030-1037.   doi: 10.1097/MNM.0000000000000547
[37] Binderup T, Knigge U, Loft A, et al.  18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors[J]. Clin Cancer Res, 2010, 16(3): 978-985.   doi: 10.1158/1078-0432.CCR-09-1759
[38] Bahri H, Laurence L, Edeline J, et al.  High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation[J]. J Nucl Med, 2014, 55(11): 1786-1790.   doi: 10.2967/jnumed.114.144386
[39] Garin E, Le Jeune F, Devillers A, et al.  Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors[J]. J Nucl Med, 2009, 50(6): 858-864.   doi: 10.2967/jnumed.108.057505
[40] Kashyap R, Hofman MS, Michael M, et al.  Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2): 176-185.   doi: 10.1007/s00259-014-2906-4
[41]

Chan DLH, Pavlakis N, Schembri GP, et al. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance[J/OL]. Theranostics, 2017, 7(5): 1149−1158[2020-08-24]. https://www.thno.org/v07p1149.htm. DOI: 10.7150/thno.18068.